Company News
January 20, 2021
BASF Expecting Better Q4
BASF Group releases preliminary figures for fourth quarter of 2020 and full year 2020
Q4 2020:
- Sales expected to be €15,905 million (Q4 2019: €14,686 million), above the prior-year quarter and above analyst consensus
- EBIT before special items expected to be €1,113 million (Q4 2019: €842 million), above the prior-year quarter and above analyst consensus
- EBIT expected to be €932 million (Q4 2019: €579 million), above the prior-year quarter and above analyst consensus
Full year 2020:
- Sales expected to be €59,149 million (2019: €59,316 million), below the prior year, above analyst consensus and above BASF forecast
- EBIT before special items expected to be €3,560 million (2019: €4,643 million), below the prior year, above analyst consensus and above BASF forecast
- EBIT expected to be –€191 million (2019: €4,201 million), below the prior year and above analyst consensus
Ludwigshafen – January 20, 2021 – BASF has released preliminary figures for the fourth quarter of 2020 and the full year 2020. Sales increased by 8 percent in the fourth quarter of 2020 to €15,905 million (Q4 2019: €14,686 million). This was mainly driven by higher volumes and prices; negative currency effects had an offsetting effect. Full year 2020 sales declined by €167 million to €59,149 million (2019: €59,316 million) and were thus above the €57 billion to €58 billion range forecast in October 2020.
The BASF Group’s operating business performed better than expected in the fourth quarter of 2020. EBIT before special items amounted to an expected €1,113 million, an increase of 32 percent compared with the prior-year quarter (Q4 2019: €842 million) and slightly above the highest analyst estimate. Compared with the third quarter of 2020, EBIT before special items rose by an expected €532 million in the fourth quarter of 2020 (Q3 2020: €581 million).
The Materials, Chemicals and Industrial Solutions segments considerably exceeded average analyst estimates for EBIT before special items in the fourth quarter of 2020. EBIT before special items fell slightly short of average analyst estimates in the Surface Technologies and Nutrition & Care segments and was considerably below analyst consensus in the Agricultural Solutions segment, mainly due to negative currency effects. In Other, EBIT before special items was less negative than expected by analysts on average.
In the full year 2020, EBIT before special items of the BASF Group amounted to an expected €3,560 million and was thus above the €3.0 billion to €3.3 billion range forecast in October 2020 and slightly above the highest analyst estimate. This corresponds to a decline of 23 percent compared with EBIT before special items for the prior year (2019: €4,643 million). The year-on-year decrease in the BASF Group’s EBIT before special items was primarily due to the considerably lower earnings contributions from the Chemicals, Surface Technologies, Materials and Agricultural Solutions segments. The Nutrition & Care segment recorded slightly lower EBIT before special items compared with the prior-year figure; in the Industrial Solutions segment, it was on a level with the previous year. The EBIT before special items of Other was significantly more negative than in 2019.
The BASF Group’s EBIT amounted to an expected €932 million in the fourth quarter of 2020, above the figure for the prior-year quarter (Q4 2019: €579 million) and above analyst consensus. In the full year 2020, EBIT declined to –€191 million (2019: €4,201 million), mainly due to the non-cash-effective impairments and provisions for restructuring in the third quarter of 2020, but was better than expected by analysts on average.
January 20, 2021
BASF Expecting Better Q4
BASF Group releases preliminary figures for fourth quarter of 2020 and full year 2020
Q4 2020:
- Sales expected to be €15,905 million (Q4 2019: €14,686 million), above the prior-year quarter and above analyst consensus
- EBIT before special items expected to be €1,113 million (Q4 2019: €842 million), above the prior-year quarter and above analyst consensus
- EBIT expected to be €932 million (Q4 2019: €579 million), above the prior-year quarter and above analyst consensus
Full year 2020:
- Sales expected to be €59,149 million (2019: €59,316 million), below the prior year, above analyst consensus and above BASF forecast
- EBIT before special items expected to be €3,560 million (2019: €4,643 million), below the prior year, above analyst consensus and above BASF forecast
- EBIT expected to be –€191 million (2019: €4,201 million), below the prior year and above analyst consensus
Ludwigshafen – January 20, 2021 – BASF has released preliminary figures for the fourth quarter of 2020 and the full year 2020. Sales increased by 8 percent in the fourth quarter of 2020 to €15,905 million (Q4 2019: €14,686 million). This was mainly driven by higher volumes and prices; negative currency effects had an offsetting effect. Full year 2020 sales declined by €167 million to €59,149 million (2019: €59,316 million) and were thus above the €57 billion to €58 billion range forecast in October 2020.
The BASF Group’s operating business performed better than expected in the fourth quarter of 2020. EBIT before special items amounted to an expected €1,113 million, an increase of 32 percent compared with the prior-year quarter (Q4 2019: €842 million) and slightly above the highest analyst estimate. Compared with the third quarter of 2020, EBIT before special items rose by an expected €532 million in the fourth quarter of 2020 (Q3 2020: €581 million).
The Materials, Chemicals and Industrial Solutions segments considerably exceeded average analyst estimates for EBIT before special items in the fourth quarter of 2020. EBIT before special items fell slightly short of average analyst estimates in the Surface Technologies and Nutrition & Care segments and was considerably below analyst consensus in the Agricultural Solutions segment, mainly due to negative currency effects. In Other, EBIT before special items was less negative than expected by analysts on average.
In the full year 2020, EBIT before special items of the BASF Group amounted to an expected €3,560 million and was thus above the €3.0 billion to €3.3 billion range forecast in October 2020 and slightly above the highest analyst estimate. This corresponds to a decline of 23 percent compared with EBIT before special items for the prior year (2019: €4,643 million). The year-on-year decrease in the BASF Group’s EBIT before special items was primarily due to the considerably lower earnings contributions from the Chemicals, Surface Technologies, Materials and Agricultural Solutions segments. The Nutrition & Care segment recorded slightly lower EBIT before special items compared with the prior-year figure; in the Industrial Solutions segment, it was on a level with the previous year. The EBIT before special items of Other was significantly more negative than in 2019.
The BASF Group’s EBIT amounted to an expected €932 million in the fourth quarter of 2020, above the figure for the prior-year quarter (Q4 2019: €579 million) and above analyst consensus. In the full year 2020, EBIT declined to –€191 million (2019: €4,201 million), mainly due to the non-cash-effective impairments and provisions for restructuring in the third quarter of 2020, but was better than expected by analysts on average.
January 15, 2021
Huntsman Completes Gabriel Acquisition
Huntsman Completes the Acquisition of Gabriel Performance Products, Further Expanding its Specialty Chemicals Portfolio
Download as PDF January 15, 2021 4:05pm EST
THE WOODLANDS, Texas, Jan. 15, 2021 /PRNewswire/ — Huntsman Corporation (NYSE: HUN) today announced it completed the acquisition of Gabriel Performance Products (Gabriel), a North American specialty chemical manufacturer of specialty additives and epoxy curing agents for the coatings, adhesives, sealants and composite end-markets, from Audax Private Equity.
Huntsman paid $250 million, subject to customary closing adjustments, in an all-cash transaction funded from available liquidity. Gabriel had 2019 revenues of approximately $106 million with three manufacturing facilities located in Ashtabula, Ohio, Harrison City, Pennsylvania and Rock Hill, South Carolina. Based on calendar year 2019, the purchase price represents an adjusted EBITDA multiple of approximately 11 times, or approximately 8 times pro forma for synergies.
January 15, 2021
Huntsman Completes Gabriel Acquisition
Huntsman Completes the Acquisition of Gabriel Performance Products, Further Expanding its Specialty Chemicals Portfolio
Download as PDF January 15, 2021 4:05pm EST
THE WOODLANDS, Texas, Jan. 15, 2021 /PRNewswire/ — Huntsman Corporation (NYSE: HUN) today announced it completed the acquisition of Gabriel Performance Products (Gabriel), a North American specialty chemical manufacturer of specialty additives and epoxy curing agents for the coatings, adhesives, sealants and composite end-markets, from Audax Private Equity.
Huntsman paid $250 million, subject to customary closing adjustments, in an all-cash transaction funded from available liquidity. Gabriel had 2019 revenues of approximately $106 million with three manufacturing facilities located in Ashtabula, Ohio, Harrison City, Pennsylvania and Rock Hill, South Carolina. Based on calendar year 2019, the purchase price represents an adjusted EBITDA multiple of approximately 11 times, or approximately 8 times pro forma for synergies.
January 15, 2021
Covestro Fire Impacts IPDI and HDI
Heavy! Some Products Of Covestro IPDI And HDI Encountered Force Majeure!
[Jan 14, 2021]
Recently, Covestro issued a letter stating that the Leverkusen plant’s isophoron diisocyanat (IPDI) and hexamethylene were caused by an accidental fire caused by Covestro IPDI and HDI in a cooling supplier in a German chemical park. The production of Hexamethyfendiisocyanat (HDI) and related derivatives of curing agents will be restricted due to force majeure. So far, it is impossible to estimate how long these effects will last.
In addition, Covestro also stated that during this period it is expected that it will not be able to meet all the ordering requirements in the next few months. We are currently doing our best to deal with the current adverse effects.
https://www.jecibiochem.com/news/heavy-some-products-of-covestro-ipdi-and-hdi-41661835.html
Everchem Updates Archive 
Sign Up for Email Updates